Table 2.
Baseline characteristics of patients in the training set stratified by status at six-month after 1st TACE.
| Baseline characteristics | Alive (n = 168) | Death within 6-month (n = 42) | P-value |
|---|---|---|---|
| Age, years, mean (SD) | 61.1 (11.0) | 59.9 (10.4) | 0.523 |
| Male sex, no. (%) | 118 (70.2) | 30 (71.4) | 1.000 |
| Cirrhosis, no. (%) | 160 (95.2) | 37 (88.1) | 0.142 |
| Etiology, no. (%) | 0.417 | ||
| HBV | 78 (46.4) | 23 (54.8) | |
| HCV | 33 (19.6) | 4 (9.5) | |
| Alcohol | 21 (12.5) | 8 (19.0) | |
| NAFLD | 17 (10.1) | 5 (11.9) | |
| Cryptogenic | 17 (10.1) | 2 (4.8) | |
| AIH | 2 (1.2) | 0 (0) | |
| Child-Pugh score, no. (%) | 0.195 | ||
| A5 | 76 (45.2) | 13 (31.0) | |
| A6 | 63 (37.5) | 18 (42.9) | |
| B7 | 29 (17.3) | 11 (26.2) | |
| Tumor characteristics | |||
| Largest tumor size, cm, median (IQR) | 3.6 (2.5, 6.1) | 7.6 (4.8, 13.7) | <0.001 |
| Largest tumor size group, cm, no. (%) | <0.001 | ||
| ≤3 | 65 (38.7) | 4 (9.5) | |
| >3–7 | 66 (39.3) | 16 (38.1) | |
| >7–10 | 21 (12.5) | 6 (14.3) | |
| >10 | 16 (9.5) | 16 (38.1) | |
| Tumor number, no., median (IQR) | 1 (1, 3) | 2 (1, 3) | 0.399 |
| Tumor number group, no. (%) | 0.560 | ||
| ≤3 | 153 (91.1) | 37 (88.1) | |
| >3 | 15 (8.9) | 5 (11.9) | |
| ALBI grade, no. (%) | 0.039 | ||
| 1 | 12 (7.1) | 0 (0) | |
| 2 | 118 (70.2) | 26 (61.9) | |
| 3 | 38 (22.6) | 16 (38.1) | |
| Laboratory results | |||
| TB, mg/dL, median (IQR) | 0.8 (0.5, 1.2) | 0.9 (0.7, 1.6) | 0.005 |
| AST, U/L, median (IQR) | 52 (37, 77) | 89.5 (62.5, 126.8) | <0.001 |
| ALT, U/L, median (IQR) | 36 (23.8, 50.5) | 48.5 (32, 69.5) | 0.007 |
| Albumin, g/dL, mean (SD) | 3.5 (0.5) | 3.3 (0.4) | 0.023 |
| Platelets, 109/L, median (IQR) | 110.5 (69, 174.2) | 170 (130, 282.8) | <0.001 |
| INR, median (IQR) | 1.2 (1.1, 1.4) | 1.2 (1.2, 1.3) | 0.731 |
| AFP, ng/mL, median (IQR) | 23.5 (7.8, 196.5) | 624.2 (33.7, 28155.8) | <0.001 |
| AFP group, ng/mL, no. (%) | <0.001 | ||
| <400 | 139 (82.7) | 21 (50.0) | |
| ≥400 | 29 (17.3) | 21 (50.0) | |
| TACE sessions, median (IQR) | 2 (1, 4) | 1 (1, 2) | <0.001 |
ABLI, albumin-bilirubin; AFP, alpha-fetoprotein; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; IQR, interquartile range; NAFLD, nonalcoholic fatty liver disease; TACE, transarterial chemoembolization; TB, total bilirubin.
Means with standard deviations and medians with IQR are shown for quantitative variables, whereas counts with proportions are shown for categorical variables. Data are expressed as medians with interquartile ranges except where noted.